Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous t-cell lymphoma

Discovery Medicine

Volumn 16, Issue 87, 2013, Pages 71-78

  Wong, Henry K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; METHOTREXATE; MICRORNA; MICRORNA 155; ROMIDEPSIN; STAT6 PROTEIN; T LYMPHOCYTE RECEPTOR; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; TUMOR MARKER;

APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CANCER PROGNOSIS; CARCINOGENESIS; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CUTANEOUS T CELL LYMPHOMA; DISEASE CLASSIFICATION; ERYTHRODERMIC PSORIASIS; GENE CONTROL; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HYPOMETHYLATION; INCIDENCE; LYMPHADENOPATHY,; META ANALYSIS (TOPIC); MYCOSIS FUNGOIDES; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PSORIASIS; SEZARY SYNDROME; SKIN DEFECT; UPREGULATION; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; SKIN NEOPLASMS;

ANIMALS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MYCOSIS FUNGOIDES; SEZARY SYNDROME; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886290618     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28(31):4730-4739, 2010.
2. Arulogun SO, Prince HM, Ng J, Lade S, Ryan GF, Blewitt O, McCormack C. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 112(8):3082-3087, 2008.
3. Bahler DW, Hartung L, Hill S, Bowen GM, Vonderheid C. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sezary syndrome by flow cytometry. Cytometry B Clin Cytom 74(3):156-162, 2008.
4. Ballabio E, Mitchell T, Van Kester MS, Taylor S, Dunlop HM, Chi J, Tosi I, Vermeer MH, Tramonti D, Saunders NJ, Boultwood J, Wainscoat JS, Pezzella F, Whittaker SJ, Tensen CP, Hatton CS, Lawrie CH. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 116(7):1105-1113, 2010.
5. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, Edelson RL. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 105(4):1640-1647, 2005.
6. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Therapeut 1(11):937-941, 2002.
7. Booken N, Gratchev A, Utikal J, Weiss C, Yu X, Qadoumi M, Schmuth M, Sepp N, Nashan D, Rass K, Tuting T, Assaf C, Dippel E, Stadler R, Klemke CD, Goerdt S. Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 22(2):393-399, 2008.
8. Borbone E, De Rosa M, Siciliano D, Altucci L, Croce CM, Fusco A. Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of Histone deacetylase inhibitors on ras-transformed thyroid cells. J Clin Endocrinol Metab 98(6):E1031-E1040, 2013.
9. Bradner JE, Greenberg E, Ponduru S, Patel V, Schreiber S, Rich B, Mazitschek R. A soft-drug histone deacetylase inhibitor for cutaneous T-cell lymphoma. Blood 110:abstr #800, 2007.
10. Buglio D, Georgakis G V, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, Younes A. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112(4):1424-1433, 2008.
11. Chong BF, Dantzer P, Germeroth T, Hafner M, Wilsona J, Xiao G, Wong HK. Induced Sezary syndrome PBMCs poorly express immune response genes up-regulated in stimulated memory T cells. J Dermatol Sci 60(1):8-20, 2010.
12. Chong BF, Wilson AJ, Gibson HM, Hafner MS, Luo Y, Hedgcock CJ, Wong HK. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 14(3):646-653, 2008.
13. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 143(7):854-859, 2007.
14. Denucci CC, Mitchell JS, Shimizu Y. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Crit Rev Immunol 29(2):87-109, 2009.
15. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, Burg G. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 88(4):1383-1389, 1996.
16. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly J F, Ricker JL, Richon VM, Frankel S R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31-39, 2007.
17. Estiu G, Greenberg E, Harrison C B, Kwiatkowski NP, Mazitschek R, Bradner JE, Wiest O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J Med Chem 51(10):2898-2906, 2008.
18. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol 14(6):427-432, 2004.
19. Garatti SA, Roscetti E, Trecca D, Fracchiolla NS, Neri A, Berti E. Bcl-1, bcl-2, p53, c-myc, and lyt-10 analysis in cutaneous lymphomas. Recent Results Cancer Res 139:249-261, 1995.
20. Gibson HM, Mishra A, Chan D V, Hake TS, Porcu P, Wong HK. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sezary syndrome. J Invest Dermatol 133(1):249-257, 2013.
21. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 350(19):1978-1988, 2004.
22. Handel AE, Ebers G C, Ramagopalan S V. Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med 16(1):7-16, 2009.
23. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sezary syndrome. Lancet 371(9616):945-957, 2008.
24. Issa JP, Kantarjian HM, Kirkpatrick P. Azacytidine. Nat Rev Drug Discov 4(4):275-276, 2005.
25. Izykowska K, Przybylski G K. Genetic alterations in Sezary syndrome. Leuk Lymphoma 52(5):745-753, 2011.
26. Jones C L, Ferreira S, Mckenzie R C, Tosi I, Caesar J A, Bagot M, Whittaker S J, Mitchell T J. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma. J Invest Dermatol 132(8):2042-2049, 2012.
27. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 115(6):885-892, 2001.
28. Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol 121(5):1045-1052, 2003.
29. Kari L, Loboda A, Nebozhyn M, Rooka H, Vonderheid E C, Nichols C, Virok D, Chang C, Horng WH, Johnston J, Wysocka M, Showe MK, Showe LC. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 197(11):1477-1488, 2003.
30. Kim YH, Liu H L, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139(7):857-866, 2003.
31. Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa J P. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112(4):1366-1373, 2008.
32. Lee CS, Ungewickell A, Bhaduri A, Qu K, Webster DE, Armstrong R, Weng WK, Aros CJ, Mah A, Chen RO, Lin M, Sundram U, Chang HY, Kretz M, Kim YH, Khavari P A. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood 120(16):3288-3297, 2012.
33. Li G, Weyand CM, Goronzy JJ. Epigenetic mechanisms of age-dependent KIR2DL4 expression in T cells. J Leukoc Biol 84(3):824-834, 2008.
34. Li G, Yu M, Weyand CM, Goronzy JJ. Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood 114(16):3422-3430, 2009.
35. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 101(4):1513-1519, 2003.
36. Mao X, Orchard G, Mitchell TJ, Oyama N, Russell-Jones R, Vermeer MH, Willemze R, Van Doorn R, Tensen C P, Young B D, Whittaker S J. A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. J Cutan Pathol 35(10):899-910, 2008.
37. Marie-Cardine A, Huet D, Ortonne N, Remtoula N, Le Gouvello S, Bagot M, Bensussan A. Killer cell Ig-like receptors CD158a and CD158b display a coactivatory function, involving the c-Jun NH2-terminal protein kinase signaling pathway, when expressed on malignant CD4+ T cells from a patient with Sezary syndrome. Blood 109(11):5064-5065, 2007.
38. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1(3):194-202, 2001.
39. Michel L, Jean-Louis F, Begue E, Bensussan A, Bagot M. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sezary syndrome diagnosis. Blood 121(8):1477-1478, 2013.
40. Mohr B, Illmer T, Oelschlagel U, Nowak R, Holig K, Paaz U, Kroschinsky F, Schuler U, Ehninger G. Complex cytogenetic and immunophenotypic aberrations in a patient with Sezary syndrome. Cancer Genet Cytogenet 90(1):33-36, 1996.
41. Morales Suarez-Varela MM, Llopis Gonzalez A, Marquina Vila A, Bell J. Mycosis fungoides: review of epidemiological observations. Dermatology 201(1):21-28, 2000.
42. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2(12):933-944, 2002.
43. Narducci MG, Arcelli D, Picchio MC, Lazzeri C, Pagani E, Sampogna F, Scala E, Fadda P, Cristofoletti C, Facchiano A, Frontani M, Monopoli A, Ferracin M, Negrini M, Lombardo G A, Caprini E, Russo G. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2:e151, 2011.
44. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110(6):1713-1722, 2007a.
45. Olsen E A, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25(21):3109-3115, 2007b.
46. Olsen E A, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim E J, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64(2):352-404, 2011.
47. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin L J, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27(32):5410-5417, 2009.
48. Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, Torrico S, Bates SE. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103(12):4636-4643, 2004.
49. Plimack ER, Kantarjian HM, Issa J P. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 48(8):1472-1481, 2007.
50. Poszepczynska-Guigne E, Schiavon V, D'incan M, Echchakir H, Musette P, Ortonne N, Boumsell L, Moretta A, Bensussan A, Bagot M. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol 122(3):820-823, 2004.
51. Qin Y, Buermans HP, Van Kester MS, Van Der Fits L, Out-Luiting JJ, Osanto S, Willemze R, Vermeer MH, Tensen CP. Deep-sequencing analysis reveals that the miR-199a2/214 cluster within DNM3os represents the vast majority of aberrantly expressed microRNAs in Sezary syndrome. J Invest Dermatol 132(5):1520-1522, 2012.
52. Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol 39(8):2076-2082, 2009.
53. Samimi S, Benoit B, Evans K, Wherry EJ, Showe L, Wysocka M, Rook AH. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol 146(12):1382-1388, 2010.
54. Su M W, Dorocicz I, Dragowska W H, Ho V, Li G, Voss N, Gascoyne R, Zhou Y. Aberrant expression of T-plastin in Sezary cells. Cancer Res 63(21):7122-7127, 2003.
55. Tang N, Gibson H, Germeroth T, Porcu P, Lim HW, Wong HK. T-plastin (PLS3) gene expression differentiates Sezary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. Br J Dermatol 162(2):463-466, 2010.
56. Van Kester MS, Ballabio E, Benner MF, Chen XH, Saunders NJ, Van Der Fits L, Van Doorn R, Vermeer M H, Willemze R, Tensen CP, Lawrie CH. miRNA expression profiling of mycosis fungoides. Mol Oncol 5(3):273-280, 2011.
57. Whittemore AS, Holly EA, Lee IM, Abel EA, Adams RM, Nickoloff BJ, Bley L, Peters JM, Gibney C. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst 81(20):1560-1567, 1989.
58. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan L M, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105(10):3768-3785, 2005.
59. Willemze R, Meijer CJ. Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. J Cutan Pathol 33(Suppl 1):18-26, 2006.
60. Wong HK. Immunopathogenesis of mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma). G Ital Dermatol Venereol 143(6):375-383, 2008.
61. Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 155(2):150-166, 2011.
62. Wong HK, Wilson AJ, Gibson HM, Hafner MS, Hedgcock CJ, Berger CL, Edelson RL, Lim HW. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides - cutaneous T cell lymphoma. J Invest Dermatol 126(1):212-219, 2006.
63. Wood GS, Hong SR, Sasaki DT, Abel EA, Hoppe RT, Warnke RA, Morhenn VB. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sezary syndrome relative to normal blood values. J Am Acad Dermatol 22(4):602-607, 1990.
64. Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 147(4):443-449, 2010.
65. Zhang C, Toulev A, Kamarashev J, Qin J Z, Dummer R, Dobbeling U. Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sezary syndrome and role of the bmi-1 and ras oncogenes in disease progression. Hum Pathol 38(7):995-1002, 2007
66. Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res 20(1):4-12, 2009